Key result
Carvedilol is being evaluated in the CAPRICORN trial, a randomized study of 1,850 patients with left ventricular dysfunction post-myocardial infarction, to assess its impact on mortality and morbidity.
Why the study?
Does carvedilol reduce all-cause mortality or cardiovascular hospitalization in patients with left ventricular dysfunction after acute myocardial infarction?
Population
Patients with confirmed acute myocardial infarction within the previous 21 days and left ventricular…
Comparison
Carvedilol up-titrated to a maximum of 25 mg… vs Placebo
Design
RCT, Automated system on a 1:1 basis, Double blind
Follow-up
Event-driven
Authors
Loading...
The CAPRICORN trial was designed to determine if the non-selective beta-blocker carvedilol reduces mortality and cardiovascular hospitalizations in patients with left ventricular dysfunction following acute myocardial infarction.
RCT (n=1,850)
Double-blind
1:1 automated system
Yes
Does carvedilol reduce all-cause mortality or cardiovascular hospitalization in patients with left ventricular dysfunction after acute myocardial infarction?
The CAPRICORN trial was designed to determine if the non-selective beta-blocker carvedilol reduces mortality and cardiovascular hospitalizations in patients with left ventricular dysfunction following acute myocardial infarction.
Henry J. Dargie (2000) conducted an RCT in Left ventricular dysfunction after acute myocardial infarction (n=1,850). Carvedilol vs. Placebo was evaluated on Co-primary: All-cause mortality or cardiovascular hospitalisation; All-cause mortality. Carvedilol is being evaluated in the CAPRICORN trial, a randomized study of 1,850 patients with left ventricular dysfunction post-myocardial infarction, to assess its impact on mortality and morbidity.